Supplement Guide for Kratom Withdrawal
Every supplement listed here is backed by clinical research. We cite our sources, explain the mechanisms, and provide specific dosing protocols organized by taper phase.
Educational Information Only
This guide presents published research for awareness purposes. It is not medical advice. Always consult a qualified healthcare provider before starting any supplement regimen, especially if you take other medications or have pre-existing health conditions.
Different supplements serve different purposes at each stage of the taper journey
Agmatine (potentiates kratom, allows lower doses), Magnesium, Vitamin C (standard dose)
Black Seed Oil, Vitamin C (megadose), Magnesium, L-Tyrosine/DLPA, Loperamide PRN
Ashwagandha, Magnesium, Kava (for anxiety), L-Tyrosine, Exercise
Tier 1: Strong Clinical Evidence
Mechanism
Thymoquinone (TQ) achieves 45% ligand displacement at mu-opioid receptors. Inhibits morphine-induced oxidative stress and nitric oxide overproduction. Attenuates tolerance and physical dependence through multiple receptor pathways.
Clinical Evidence
Human clinical trial (Sangi et al., 2008) with 35 opioid-dependent subjects. Subjective withdrawal scores dropped from 63.2±13.57 to 14.56±8.13 by day 12. Objective signs reduced from 25.52±3.08 to 7.72±2.35.
Source: Sangi et al. (2008); Adnan et al. (2020) PMC7395189
Dosage
500mg three times daily with meals
Timing
Morning, midday, evening with food
Warnings
- May lower blood sugar — monitor if diabetic
- May interact with blood thinners
Mechanism
Endogenous amine that binds imidazoline receptors, α2-adrenergic receptors, NMDA receptors, and serotonin receptors. Blocks naloxone-precipitated morphine withdrawal. Prevents opioid tolerance development. Critically, agmatine potentiates remaining kratom effects during taper — allowing lower doses to feel more effective.
Clinical Evidence
Extensive animal studies (Wu et al., 2007; Kolesnikov et al., 1996). Enhanced morphine analgesia, inhibited tolerance, blocked withdrawal symptoms. Widely confirmed by the r/quittingkratom community as one of the most effective supplements.
Source: Wu et al. (2007) PMC11515036; Kolesnikov et al. (1996)
Dosage
500mg–1g daily
Timing
30 minutes before kratom dose for maximum potentiation
Warnings
- May lower blood pressure
- Take separately from protein-rich meals for best absorption
Mechanism
Potent antioxidant that modulates opioid receptor signaling and reduces oxidative stress during withdrawal. The megadose protocol (sodium ascorbate form) has been clinically studied for opioid withdrawal specifically.
Clinical Evidence
Human clinical trials (Evangelou et al., 2000; PMC7572147). Reduced general withdrawal symptoms, decreased craving, improved sense of well-being. Does not significantly inhibit CYP3A4, making it safe to combine with kratom during taper.
Source: Evangelou et al. (2000); PMC7572147
Dosage
300mg per kg body weight (megadose protocol). For a 170lb person: approximately 23g/day divided into 4–6 doses
Timing
Divided throughout the day. Use sodium ascorbate form to avoid GI distress at high doses.
Warnings
- Use sodium ascorbate, NOT ascorbic acid at high doses (GI distress)
- May cause loose stools — reduce dose if this occurs
- Consult physician if history of kidney stones
Tier 2: Moderate Evidence / Strong Anecdotal
Mechanism
Mild NMDA receptor antagonist, muscle relaxant, and natural sleep aid. Reduces anxiety, muscle cramps, and restless leg syndrome — three of the most common kratom withdrawal symptoms.
Evidence
Clinical consensus for opioid withdrawal support. Glycinate form preferred for lowest GI upset and highest bioavailability.
Source: Multiple clinical references; SAMHSA guidelines
Dosage
400–800mg magnesium glycinate daily
Timing
200–400mg morning, 200–400mg before bed (sleep benefit)
Warnings
- Use glycinate or gluconate forms only — oxide form has poor absorption
- May cause drowsiness at higher doses
Mechanism
Adaptogen that modulates cortisol, enhances GABA signaling, and increases dopamine and serotonin. Particularly effective for the anxiety and depression that accompany withdrawal.
Evidence
Animal studies (Ahmed et al., 2025) showed significant increases in dopamine and serotonin in withdrawal subjects. Strong traditional evidence and widespread use in recovery communities.
Source: Ahmed et al. (2025) — Tramadol withdrawal study
Dosage
300–600mg KSM-66 extract daily
Timing
Morning with food. Avoid during active taper as it may potentiate sedative effects.
Warnings
- May interact with CYP2D6 substrates
- May potentiate sedation during early taper — best for recovery phase
- Avoid if thyroid condition without physician guidance
Mechanism
Kavalactones modulate GABA-A receptors, producing anxiolytic and muscle relaxant effects comparable to benzodiazepines in some clinical studies.
Evidence
Multiple human clinical trials demonstrating clinically significant anxiety reduction. Logical application to withdrawal-related anxiety.
Source: Multiple clinical trials for generalized anxiety
Dosage
120–240mg kavalactones daily
Timing
Evening, for anxiety and sleep support
Warnings
- Hepatotoxicity risk with poor-quality extracts — use only noble kava varieties
- Do NOT combine with alcohol
- Potential CYP2D6 inhibitor
- Do NOT use while still taking kratom (both hepatotoxic in rare cases)
Mechanism
L-Tyrosine is a direct precursor to dopamine and norepinephrine. DLPA (DL-Phenylalanine) inhibits enkephalinase, preserving endogenous opioids. Together they support the depleted neurotransmitter systems that cause post-withdrawal fatigue and anhedonia.
Evidence
Sound biochemical logic with widespread anecdotal support. Amino acid precursor therapy is well-established in addiction medicine.
Source: General clinical references; amino acid precursor therapy literature
Dosage
L-Tyrosine 500–2000mg morning on empty stomach; DLPA 500–1500mg daily
Timing
Morning on empty stomach, 30 minutes before food
Warnings
- Avoid if taking MAOIs
- May cause headaches at high doses
- Start low and increase gradually
Tier 3: Supportive / Emerging
CBD (Cannabidiol)
Use: Anxiety, inflammation, cravings
Emerging clinical trials for opioid cravings. Legal in most states.
Dosage: 25–50mg full-spectrum daily
Valerian Root
Use: Sleep support
Clinical evidence for insomnia. Useful for the sleep component of withdrawal.
Dosage: 300–600mg before bed
Loperamide (Imodium)
Use: GI symptoms (diarrhea)
Peripheral mu-opioid agonist. Standard of care for withdrawal diarrhea. WARNING: Cardiac toxicity at high doses — never exceed package directions.
Dosage: Standard OTC dosing ONLY
Melatonin
Use: Sleep onset
Low doses more effective than high doses. Helps reset circadian rhythm.
Dosage: 0.5–3mg 30 min before bed
- Kratom inhibits CYP3A4 and CYP2D6 — supplements metabolized by these enzymes may have altered effects during taper
- Kava + kratom = potential hepatotoxicity risk (both hepatotoxic in rare cases) — use kava only after kratom is discontinued
- Ashwagandha may potentiate sedative effects during early taper — reserve for recovery phase
- High-dose Vitamin C: use sodium ascorbate form to avoid severe GI distress
- Agmatine potentiates remaining kratom effects during taper — this is beneficial (allows lower doses) but be aware of the interaction
Get Your Personalized Supplement Schedule
Our calculator generates a day-by-day plan that tells you exactly which supplements to take, when, and at what dose — timed to your specific taper phase.
This supplement guide is for educational and awareness purposes only. It is not medical advice. The information presented is based on published research cited above. Always consult a qualified healthcare provider before starting any supplement regimen. Individual results vary. If you experience adverse effects, discontinue use and seek medical attention.